Our study systematically and comprehensively validates that LGALS2 can be used as a diagnostic/prognostic marker for breast cancer, especially a good diagnostic marker for TNBC, and that it participates in tumor immunotherapy by regulating T cells. This evidence concerns the gene LGALS2 and breast cancer.